In the MARIPOSA trial, amivantamab plus lazertinib was compared to osimertinib (the current standard of care third-generation EGFR TKI) in the first-line treatment of EGFR-mutant NSCLC, and the incidence of pneumonitis or ILD was similar, with an incidence of 3% in both groups, including grade 3 or higher events in 1% of patients in both treatment arms [31]. This evidence concerns the gene EGFR and pneumonitis.